PR Newswire
PORTLAND, Ore., April 29, 2026
Increasing Incidence of Neurological Disorders, Technological Advancements in Shunt Systems, and Growing Geriatric Population Propel Market Growth
PORTLAND, Ore., April 29, 2026 /PRNewswire/ — Allied Market Research recently published a new report, titled, «Hydrocephalus Market by Cause, Type, Diagnosis & Treatment (Shunt Surgery and Endoscopic Third Ventriculostomy), by Age Group (Infant and Adult): Opportunity Analysis and Industry Forecast 2021-2030.» It provides a comprehensive market strategies, sectors, competitive landscape, and regional insights into the global hydrocephalus that aim to deliver an actionable intelligence on different facets of the hydrocephalus at play in order to aid stakeholders across neurology and medical device sector.
https://mma.prnewswire.com/media/636519/5918347/Allied_Market_Research_Logo.jpg
Market Size & Growth
Global Hydrocephalus Market Size (2020) and Forecast (2030) The global hydrocephalus market was worth $6.90 billion in 2020, and it is poised to keep its exponential CAGR growth of 4.0% by producing a revenue of $10.17 billion in 2030. This steady growth path is driven most notably by; the rising burden of neurological disorders globally, the aging population globally who are more vulnerable to CSF complications as well as ever-evolving neurosurgical treatment machinery.
A common disorder involving the accumulation of cerebrospinal fluid (CSF) in all or part of the ventricular system within the brain, hydrocephalus occurs in one to two out of every 1,000 newborns around the world (National Institute of Neurological Disorders and Stroke [NINDS], 2023). Over 1 million people currently live with this chronic neurological disease in the U.S. alone, and a hydrocephalus-related brain surgery is performed every 15 minutes. These numbers highlight the substantial and persistent clinical demand for effective diagnosis and treatment solutions.
Key Market Insights
A multitude of macro and micro-economic factors are shaping the hydrocephalus market. On the one hand, the progressive increase in neurological disorders like brain tumors, intraventricular hemorrhage, stroke, spinal cord injuries, and CSF infections are directly linked with an increasing number of hydrocephalic populations. And other than this, the rapid growth in geriatric population across the globe is supporting long term demand due to fact 1 million elderly will experience hydrocephalus in USA.
On the supply side, uptake of modern programmable valves which are easily adjustable to external changes in CSF drainage pressure without repeat surgery or other invasive measures by neurosurgeons improves patient outcomes as well as minimizes revision surgery rates. This has led to the development of minimally invasive surgical strategies, such as endoscopic third ventriculostomy (ETV), providing a shunt-free alternative for patients, and increasing the size of the treatable patient population. Shunt complications such as infection, malfunctioning devices, over-drainage and in rare cases irreversible brain injury or meningitis are hurdles impacting the marketplace; these factors continue to limit wider adoption and the push for R&D spend towards more robust next-generation devices.
The combination of sophisticated diagnostic imaging (MRI, CT and ultrasound), novel shunt technology, and increased patient awareness are substantially altering the hydrocephalus care paradigm while delivering commercial opportunities for industry stakeholders.
Request Sample of the Report on hydrocephalus market:
https://www.alliedmarketresearch.com/request-sample/A14991
Market Segmentation
Market Segmentation: Hydrocephalus market is segmented in detail based on cause, type, diagnosis, treatment and age group.
By Cause: The hydrocephalus segment accounted for the highest revenue share of over half of the global market in 2020, owing to increasing incidences of neurological injuries and CSF infections. Conversely, the segment for congenital hydrocephalus is expected to witness the highest CAGR of 4.3% over the forecast period owing to rising neonatal screening and early diagnosis.
Market by Type: Communicating hydrocephalus–which includes normal pressure hydrocephalus (NPH) and ex-vacuo hydrocephalus–continues to dominate the market. The second main category is non-communicating (obstructive) hydrocephalus, which almost always necessitates surgical CSF diversion.
By Diagnosis: Ultrasound dominated diagnosis methodology and is expected to maintain its dominance due to its non-invasiveness and common use in neonates. The MRI and CT scan segments are also important to clinical diagnosis workflows.
By Treatment: Shunt insertion (surgery) is the most widely used treatment modality and also has a significant commercial presence in the hydrocephalus devices market. Endoscopic third ventriculostomy (ETV) is gaining momentum as a minimally invasive alternative.
On the basis of Age, the adults segment dominated the share of market in 2020 and is anticipated to display highest CAGR of 4.3% from 2021-2030. It is mainly attributed to the increasing number of patients with acquired hydrocephalus in the geriatric population, especially normal pressure hydrocephalus (NPH) among people aged over 60.
Regional Insights
North America: The highest revenue was share out of one-fifth half a decade was reported in North America in 2020 and this large value fraction of its kind is attributable to the region’s high-tech healthcare infrastructure with great unique rates for neurosurgical procedures per capita, innovational results and progressive R&D investments a long with early adoption premium programmable shunt systems. The U.S. represents the area anchor market given optimal reimbursement policies and a large, diagnosed base of hydrocephalus patients.
Europe – Europe is the second largest regional market, reflecting well-developed public healthcare systems in Germany, France and the U.K., rapid adoption of advanced neurosurgical technologies, and ongoing clinical research programs. Neurology-specific healthcare infrastructure in the region will likely continue to benefit from rising government support.
Asia-Schiller: Asia-Pacific is a regional market with the highest growth rate in terms of revenue and is expected to register the highest CAGR of 5.0% during forecast period from 2021 to 2030. The growth of the market is propelled by improving accessibility to healthcare, increasing awareness about minimally invasive neurosurgical procedures, high incidence of stroke and CSF disorders at a higher rate across China, India, Japan, and Southeast Asian economies that are urbanizing rapidly. Shunt systems manufactured locally at affordable prices also are improving treatment access for lower-income populations.
LAMEA (Latin America, Middle East & Africa): LAMEA is an emerging opportunity space, where improving healthcare systems along with an increase in neural surgical awareness and government supported neonatal health programs are slowly fueling the hydrocephalus treatment market across Brazil, South Africa and Saudi Arabia.
Want to Explore More, Connect to our Analyst – https://www.alliedmarketresearch.com/connect-to-analyst/A14991
Key Players
Executive Summary–The Global Hydrocephalus Market: Industry Insights, Market Dynamics & Competitive Landscape |Data Bridge Market Research; 2022 to 2030. Copyright @ Data Bridge Market Research Introduction The competitive landscape of the global hydrocephalus market is moderately consolidated with few leading and established medical device companies holding a major part of the share followed by emerging start-ups in key geographies globally. Allied Market Research report the major companies are profiled asset al.
Medtronic Plc: A global neurosurgical powerhouse endowed by its flagship Strata programmable valve systems and Nightwatch anti-siphon technology. Medtronic has a dominant share of the shunt market and pours resources into R&D for lessening shunt disappointment rates.
Integra LifeSciences Corporation — Has a broad shunt portfolio catering to pediatric and adult hydrocephalus cases including precision CSF management from programmable valves in addition to an antimicrobial catheter coating.
B. Braun, Aesculap Inc (Aesculap Inc.) — Key Neurosurgical device companies with Product strategies: Comprehensive product portfolio including shunt systems Wide-ranging distribution network across developed and emerging markets
Karl Storz SE & Co. KG: Manufacturer of endoscopic neurosurgical instruments and shunt-free alternative supported by its minimally invasive ventriculostomy procedures
Sophysa / Tokibo Co. Ltd.: Known for tunable CSF valve technologies & international expansion.
Natus Medical Incorporated – Provide neurodiagnostic and newborn care solutions and form a part of the diagnostic element of hydrocephalus ecosystem.
Key Recent Industry Developments
The U.S. Department of Defense (DoD) has awarded a $5.6 million grant to Senseer Health Inc. to develop its MultiSense microsensor, or multi-sensing, technology for real-time and non-invasive monitoring of hydrocephalus shunts — an innovation for remote patient monitoring for neurological implants: July 2024
Surgeons at Intermountain Primary Children’s Hospital (Utah, U.S.) performed a first-in-kids procedure last November. They successfully implanted Anuncia Medical’s Reflow Mini Flusher, an advanced shunt accessory specifically designed to reduce revision surgery risk in pediatric hydrocephalus patients.
The improvement of this CSF pressure modulation system aimed to be a long-lasting implant which makes the patient have less shunt revisions April 2021: Medtronic began marketed their StrataMR II programmable valve system systems, enhancing the MRI-compatible and multi-setting CSF control.
June 2021: Cranial Devices Inc. (a spin-out company from Penn State University) has launched HydroFix, a high-technology shunt system with an integrated CSF drain that is targeted towards the greatest unique and unmet clinical need of decreased risk of surgical failure for shunts.
June 2020: CereVasc obtained $43.9M in Series A funding to develop a unique, minimally invasive endovascular replacement for traditional shunt surgery, representing perhaps the most disruptive hydrocephalus treatment innovation in years.
In September 2019, Integra LifeSciences acquired Arkis Biosciences Inc., developer of next generation CSF management solutions and technologies which enhances the overall thoroughness of Integra’s neurosurgical product lineup specifically in the hydrocephalus space.
For Purchase Related Queries/Inquiry –
https://www.alliedmarketresearch.com/purchase-enquiry/A14991
Leading Market Players
- Aesculap Inc.
- Integra Lifesciences
- Karl Storz Se And Co. Kg
- Proteses Inc.
- Medtronic Plc.
- Natus Medical Inc.
- Boston Children’s Hospital
- Anadolu Medical Center
- Helios Hospital
- Texas Children’s Hospital
- Children’s National Hospital
Analyst Review
Commenting on the report, a Senior Healthcare Analyst at Allied Market Research said, «The hydrocephalus market is poised for inflection due to twin forces: the rapid increase of neurological disease burden and unprecedented innovation from neurosurgical device technology.» Endoscopic procedures, programmable shunt systems and real-time monitoring solutions converge to place this market in a good position to not only tackle clinical efficacy but also patient quality-of-life outcomes for the next decade.
Get access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
Trending Reports in Healthcare Industry:
Pharmacovigilance Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Pet DNA Testing Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Postpartum Hemorrhage (PPH) Devices Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Pediatric Ultrasound Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Light Therapy Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Medical Imaging Informatics Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of «Market Research Reports» and «Business Intelligence Solutions.» AMR has a targeted view to provide business insights and consulting to assist its clients in making strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies, and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality data and help clients in every way possible to achieve success. Every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa1209 Orange Street,Corporation Trust Center,Wilmington, New Castle,Delaware 19801 USA.Toll Free: +1-800-792-5285Int’l: +1-503-894-6022UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: [email protected]
Logo – https://mma.prnewswire.com/media/636519/5918347/Allied_Market_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/global-hydrocephalus-market-is-projected-to-reach-usd-10-17-billion-by-2030–302757617.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…